

**H.R. 986, Protecting Americans with Preexisting Conditions Act of 2019**

As ordered reported by the House Committee on Energy and Commerce on April 3, 2019

| Millions of Dollars  | 2019 | 2019-2024                           | 2019-2029 |
|--|------|-------------------------------------|-----------|
| Direct Spending (Outlays)  | 0    | *                                   | *         |
| Revenues   | 0    | *                                   | *         |
| Deficit Effect   | 0    | *                                   | *         |
| Spending Subject to Appropriation (Outlays)  | 0    | 0                                   | 0         |
| Pay-as-you-go procedures apply?  | Yes  | <b>Mandate Effects</b>              |           |
| Increases on-budget deficits in any of the four consecutive 10-year periods beginning in 2030? | No   | Contains intergovernmental mandate? | No        |
|  |      | Contains private-sector mandate?    | No        |
| * = between -\$500,000 and \$500,000.  |      |                                     |           |

H.R. 986 would prohibit the Departments of Health and Human Services and the Treasury from taking any action to implement or enforce the regulatory guidance entitled “State Relief and Empowerment Waivers” or from issuing similar guidance in the future. Under current law and this legislation, waivers are required to be budget neutral. Changes to waiver approvals could affect direct spending and revenues; however, CBO and JCT do not have a basis for estimating that the budgetary effects of the bill would be significantly different than under current law because no states have submitted a waiver application under the guidance that would be eliminated by this legislation. As a result, CBO and JCT estimate that H.R. 986 would not have a significant effect on direct spending or revenues over the 2019-2029 period.

The CBO staff contact for this estimate is Kevin McNellis. The estimate was reviewed by Leo Lex, Deputy Assistant Director for Budget Analysis.